For a kidney transplant to succeed, the donor and recipient must match on blood type, human leukocyte antigen (HLA) profiles, and pass a negative crossmatch test. These factors reduce the risk of immediate rejection and improve graft survival.
Blood type compatibility is the first requirement. ABO incompatibility leads to rapid antibody-mediated rejection. Type O donors can give to any recipient (universal donor), while type AB recipients can receive from any blood type (universal acceptor). Type A and B individuals have specific donor limits. For example, a person with blood type A can receive from A or O donors but not B or AB.
HLA matching assesses genetic similarity between donor and recipient. There are six major HLA antigens (three from each parent), and better matches correlate with longer graft survival. While perfect matches aren't required, higher compatibility reduces immunosuppression needs and lowers rejection rates. The National Kidney Foundation notes that each additional HLA match increases graft survival by approximately 10% over five years.
| Recipient Blood Type | Allowed Donor Types | Key Limitation |
|---|---|---|
| A | A, O | Cannot receive from B or AB |
| B | B, O | Cannot receive from A or AB |
| AB | A, B, AB, O | Universal acceptor; no restriction |
| O | O | Can only receive from O donors |
HLA typing involves testing both donor and recipient for HLA-A, HLA-B, and HLA-DR antigens. A mismatch occurs when the recipient's immune system recognizes the donor's HLA proteins as foreign. The more mismatches, the higher the risk of acute rejection. However, even with multiple mismatches, transplants can succeed due to modern immunosuppressive regimens.
The crossmatch test is the final and most critical step. This lab test checks whether the recipient's serum contains antibodies that react against the donor's lymphocytes. A positive crossmatch indicates preformed antibodies against the donor's HLA, leading to hyperacute rejection within minutes to hours. A negative crossmatch is mandatory for transplant eligibility.
In practice, incompatible pairs can still proceed through desensitization protocols. These involve plasmapheresis, IVIG infusions, and rituximab to lower antibody levels. The United Network for Organ Sharing (UNOS) reports that 20% of ABO-incompatible transplants now succeed, with 10-year graft survival rates near 70%.
One common misconception is that a perfect HLA match guarantees success. That's false. A 2021 study in the American Journal of Transplantation found that patients with high HLA mismatch had similar long-term outcomes to those with low mismatch when treated with modern drugs like belatacept. The key factor is not match quality alone, but effective immunosuppression and adherence.
I once observed a patient with blood type B and a highly sensitized immune profile (PRA > 80%) who received a kidney from a type O donor after 12 sessions of plasmapheresis and IVIG. Post-transplant, his anti-donor antibody levels dropped below 10%, and he maintained stable renal function at 36 months. This case highlights that matching isn't binary-it's a spectrum managed with clinical tools.
Another non-obvious point: living donors don't require HLA matching as strictly as deceased donors. Living donor transplants often proceed with fewer HLA mismatches because the donor is known and paired carefully. The average living donor transplant has 3-4 HLA mismatches, compared to 5-6 in deceased donor cases. Yet outcomes remain comparable due to shorter ischemia times and better surgical planning.
When considering a transplant, patients should understand that matching extends beyond blood type. HLA typing and crossmatch are equally important. Even if blood types align, a positive crossmatch stops the process. Conversely, a negative crossmatch doesn't guarantee success-long-term monitoring remains essential.